Multiple fields may offer better esophagus sparing without increased probability of lung toxicity in optimized IMRT of lung tumors

International Journal of Radiation Oncology Biology Physics

Volumn 65, Issue 1, 2006, Pages 255-265

  Chapet, Olivier ^a   Fraass, Benedick A ^a   Ten Haken, Randall K ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Equivalent uniform dose; Intensity modulated radiation therapy; Lung cancer; Normal tissue complication probability; Optimization

Indexed keywords

DOSIMETRY; OPTIMIZATION; PROBABILITY; RADIOTHERAPY; TISSUE;

EQUIVALENT UNIFORM DOSE; INTENSITY-MODULATED RADIATION THERAPY; LUNG CANCER; NORMAL TISSUE COMPLICATION PROBABILITY;

BIOLOGICAL ORGANS;

ARTICLE; CANCER LOCALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DOSIMETRY; ESOPHAGUS; ESOPHAGUS DISEASE; HEART; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG CANCER; LUNG TOXICITY; PRIORITY JOURNAL; PROBABILITY; RADIATION DOSE; THREE DIMENSIONAL IMAGING; TREATMENT PLANNING; TUMOR VOLUME;

ESOPHAGUS; HEART; HUMANS; LUNG; LUNG NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; SPINAL CORD;

EID: 33645990000     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.12.028     Document Type: Article

References (61)

1. Rosenzweig K.E., Mychalczak B., Fuks Z., et al. Final report of the 70.2Gy and 75.6Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer. Cancer J 6 (2000) 82-87
2. Hayman J.A., Martel M.K., Ten Haken R.K., et al. Dose escalation in non small-cell lung cancer using three-dimensional conformal radiation therapy. Update of a phase I trial. J Clin Oncol 19 (2001) 127-136
3. Wu K.-L., Jiang G.-L., Liao Y., et al. Three dimensional conformal radiation therapy for non small cell lung cancer. A phase I/II dose escalation clinical trial. Int J Radiat Oncol Biol Phys 57 (2003) 1336-1344
4. Belderbos J.S.A., De Jaeger K., Heemsbergen W.D., et al. First results of a phase I/II dose escalation trial in non-small cell lung cancer using three dimensional conformal radiotherapy. Radiother Oncol 66 (2003) 119-126
5. Jeremic B., Shibamoto Y., Acimovic L., et al. Randomized trial for hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small lung cancer. J Clin Oncol 13 (1995) 452-458
6. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
7. Curran W., Scott C., Langer C., et al. Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small-cell lung cancer (NSCLC). Initial report of Radiation Therapy Oncology Group (RTOG) 9410. (Abstr). Proc Am Soc Clin Oncol 19 (2000) 1891a
8. Lee J.S., Scott C., Komaki R., et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancer. Radiation Therapy Oncology Group Protocol 91-06. J Clin Oncol 14 (1996) 1055-1064
9. Lee J.S., Komaki R., Fossella F.V., et al. A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small-cell lung cancer. A 5 year follow-up report. Int J Radiat Oncol Biol Phys 42 (1998) 479-486
10. Lopez-Picazo J.M., Azinovic I., Aristu J.J., et al. Induction platinum based chemotherapy followed by radical hyperfractionated radiotherapy with concurrent chemotherapy in the treatment of locally advanced non-small cell carcinoma of the lung. Am J Clin Oncol 22 (1999) 203-208
11. Socinski M.A., Rosenman J.G., Halle J., et al. Dose escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/IIIB non-small cell lung carcinoma. A modified phase I/II trial. Cancer 92 (2001) 1213-1223
12. Lee S.-S., Choi E.K., Lee J.S., et al. Phase II study of three dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for stage III locally advanced, unresectable, non-small cell lung cancer. Int J Radiat Oncol Biol Phys 56 (2003) 996-1004
13. Choy H., Akerley W., Safran H., et al. Multiinstitutional phase II trial of paclitaxel carboplatin and concurrent radiation therapy for locally advanced non-small cell lung cancer. J Clin Oncol 16 (1998) 3316-3322
14. Werner-Wasik M., Scott C., Graham M.V., et al. Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy. A multivariate analysis of 1076 RTOG patients. Int J Radiat Oncol Biol Phys 44 (1999) 327-331
15. Lau D., Leigh B., Gandara D., et al. Twice weekly paclitaxel and weekly carboplatin with concurrent thoracic irradiation followed by carboplatin/paclitaxel consolidation for stage III non-small cell lung cancer. A California Cancer Consortium phase II trial. J Clin Oncol 19 (2001) 442-447
16. Komaki R., Lee J.S., Milas L., et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small cell lung cancer. Report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58 (2004) 1369-1377
17. Grills I.S., Yan D., Martinez A.A., et al. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer. A comparison of intensity modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys 57 (2003) 875-890
18. Lui H.H., Wang X., Dong L., et al. Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 58 (2004) 1268-1279
19. Murshed H., Liu H.H., Liao Z., et al. Dose and volume reduction for normal lung using intensity modulated radiotherapy for advanced stage non small cell lung cancer. Int J Radiat Oncol Biol Phys 58 (2004) 1258-1267
20. Tomé A., and Fowler J. Selective boosting of tumor subvolumes. Int J Radiat Oncol Biol Phys 48 (2000) 593-599
21. Deasy J.O. Partial tumor boosts. Even more attractive than theory predicts. Int J Radiat Oncol Biol Phys 51 (2001) 279-280
22. Engelsman M., Remeijer P., van Herk M., et al. Field size reduction enables Iso-NTCP escalation of tumor control probability for irradiation of lung tumors. Int J Radiat Oncol Biol Phys 51 (2001) 1290-1298
23. Engelsman M., Remeijer P., van Herk M., et al. Theoretical benefit of beam fringe compensation and field size reduction for iso-normal tissue complication probability dose escalation radiotherapy of lung cancer. Med Phys 30 (2003) 1086-1095
24. Schwarz M., Alber M., Lebesque J.V., et al. Dose heterogeneity in the target volume and intensity-modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 62 (2005) 561-570
25. Chapet O., Thomas E., Kessler M.L., et al. Esophagus sparing in lung tumor irradiation. An EUD-based optimization technique. Int J Radiat Oncol Biol Phys 63 (2005) 179-187
26. Yorke E.D., Jackson A., Rosenzweig K.E., et al. Correlation of dosimetric factors and radiation pneumonitis incidence for non-small cell lung cancer (NSCLC) patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys 63 (2005) 672-682
27. Hashimoto T., Shirato H., Kato M., et al. Real-time monitoring of a digestive tract marker to reduce adverse effects of moving organs at risk (OAR) in radiotherapy for thoracic and abdominal tumors. Int J Radiat Oncol Biol Phys 61 (2005) 1559-1564
28. Mackie T.R., Scrimger J.W., and Battista J.J. A convolution method of calculating dose for 15MV x rays. Med Phys 12 (1985) 188-196
29. Roberson J.M., Ten Haken R.K., Hazuka M.B., et al. Dose escalation for non-small cell lung cancer using conformal radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1079-1085
30. Vineberg K.A., Eisbruch A., Coselmon M.A., et al. Is uniform target dose possible in IMRT plans in head and neck?. Int J Radiat Oncol Biol Phys 52 (2002) 1159-1172
31. Kessler M., McShan D., Vineberg K., et al. Costlets. A generalized approach to cost functions for automated optimization. Optimization Eng. 6 (2005) 421-448
32. Niemierko A. A generalized concept of equivalent uniform dose (EUD) (Abstr.). Med Phys 26 (1999) 1100
33. Wu Q., Mohan R., Niemierko A., et al. Optimization of intensity modulated radiotherapy plans based on the equivalent uniform dose. Int J Radiat Oncol Biol Phys 52 (2002) 224-235
34. Choy B., and Deasy J.O. The generalized equivalent uniform dose function as a basis for intensity-modulated treatment planning. Phys Med Biol 47 (2002) 3579-3589
35. Lyman J.T. Complication probability as assessed from dose volume histograms. Radiat Res 8 Suppl (1985) S13-S19
36. Kutcher G.J., and Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation. The effective volume model. Int J Radiat Oncol Biol Phys 16 (1989) 1623-1630
37. Burman C., Kutcher G.J., Emami B., et al. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys 21 (1991) 123-135
38. Seppenwoolde Y., Lebesque J.V., De Jaeger K., et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Int J Radiat Oncol Biol Phys 55 (2003) 724-735
39. Graham M.V., Purdy J.A., Emami B., et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 45 (1999) 323-329
40. Marks L.B., Munley M.T., Bentel G.C., et al. Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys 39 (1999) 563-570
41. Thomas E., Chapet O., Kessler M.L., et al. The benefit of using biological parameters (EUD and NTCP) in IMRT optimization for the treatment of intrahepatic tumors. Int J Radiat Oncol Biol Phys 62 (2005) 571-578
42. Holloway C.L., Robinson D., Murray B., et al. Results of a phase I study to dose escalate using intensity modulated radiotherapy guided by combined PET/CT imaging with induction chemotherapy for patients with non-small cell lung cancer. Radiother Oncol 73 (2004) 285-287
43. Lawrence T.S., Hayman J., Martel M., et al. Regarding predicting radiation response. Int J Radiat Oncol Biol Phys 41 (1998) 972
44. De Neve W., and De Wagter C. Lethal pneumonitis in a phase I study of chemotherapy and IMRT for NSCLC. The need to investigate the accuracy of dose computation. Radiother Oncol 75 (2005) 246-247
45. Chetty I.J., Charland P.M., Tyagi N., et al. Photon beam relative dose validation of the DPM Monte Carlo code in lung-equivalent media. Med Phys 30 (2003) 563-573
46. Senan S., Chapet O., Lagerwaard F.J., et al. Defining target volumes for non-small cell lung carcinoma. Semin Radiat Oncol 14 (2004) 308-314
47. Seppenwoolde Y., Shirato H., Kitamura K., et al. Precise and real time measurement of 3D tumor motion in lung due to breathing and heartbeat, measured during radiotherapy. Int J Radiat Oncol Biol Phys 53 (2002) 822-834
48. van Sornsen de Koste J.R., Lagerwaard F.J., Nijssen-Visser M.R., et al. What margins are necessary for incorporating mediastinal nodal mobility in involved-filed radiotherapy for lung cancer?. Int J Radiat Oncol Biol Phys 53 (2002) 1211-1215
49. Sher D.J., Wolfgang J., Niemierko A., et al. Quantification of mediastinal lymph node movement using 4D CT scan. implications for radiation treatment planning. (Abstr). Int J Radiat Oncol Biol Phys 63 Suppl 1 (2005) S222-S223
50. Thomas J.G., Koshani R., Balter J.M., et al. Intra- and inter-fraction mediastinal nodal region motion. implications for internal target volume expansions. (Abstr). Int J Radiat Oncol Biol Phys 63 Suppl. 1 (2005) S409
51. Mah D., Hanley J., Rosenzweig K.E., et al. Technical aspects of the deep inspiration breath hold technique in the treatment of thoracic cancer. Int J Radiat Oncol Biol Phys 48 (2000) 1175-1185
52. Hanley J., Debois M.M., Mah D., et al. Deep inspiration breath hold technique for lung tumors. The potential value of target immobilization and reduced lung density in dose escalation. Int J Radiat Oncol Biol Phys 45 (1999) 603-611
53. Rosenzweig K.E., Hanley J., Mah D., et al. The deep inspiration breath hold technique in the treatment of inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 48 (2000) 81-87
54. Wong J.W., Sharpe M.B., Jaffray D.A., et al. The use of active breathing control (ABC) to reduce margin for breathing motion. Int J Radiat Oncol Biol Phys 44 (1999) 911-919
55. Cheung P.C.F., Sixel K.E., Tirona R., et al. Reproducibility of lung tumor position and reduction of lung mass within the planning target volume using active breathing control (ABC). Int J Radiat Oncol Biol Phys 57 (2003) 1437-1442
56. Wilson E.M., Williams F.J., Lyn B.E., et al. Validation of active breathing control in patients with non-small-cell lung cancer to be treated with CHARTWEL. Int J Radiat Oncol Biol Phys 57 (2003) 864-874
57. Ford E.C., Chang J., Mueller K., et al. Cone-beam CT with megavoltage beams and an amorphous silicon electronic portal imaging device. Potential for verification of radiotherapy of lung cancer. Med Phys 29 (2002) 2913-2924
58. Sonke J.-J., Zijp L., Remeijer P., et al. Respiratory correlated cone beam CT. Med Phys 32 (2005) 1176-1186
59. Erridge S.C., Seppenwoolde Y., Muller S.H., et al. Portal imaging to assess set-up errors, tumor motion and tumor shrinkage during conformal radiotherapy of non-small cell lung cancer. Radiother Oncol 66 (2003) 75-85
60. Damen E., Wolthaus J., van Herk M., et al. Image-guided radiotherapy for lung cancer. Respiration-correlated (cone-beam) CT to verify tumor position and motion characteristics during treatment delivery. (Abstr). Int J Radiat Oncol Biol Phys 60 Suppl 1 (2004) S198
61. Kupelian P.A., Ramsey C., Meeks S.L., et al. Serial megavoltage CT imaging during external beam radiotherapy for non-small-cell lung cancer. Observations on tumor regression during treatment. Int J Radiat Oncol Biol Phys 63 (2005) 1024-1028